Incyte (INCY)
(Delayed Data from NSDQ)
$75.59 USD
+0.70 (0.93%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $75.60 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Incyte Corporation has a PEG ratio of 0.57 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INCY 75.59 +0.70(0.93%)
Will INCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Incyte (INCY) is a Top Value Stock for the Long-Term
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for INCY
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News
Incyte (INCY) Receives Overweight Rating and $90 Price Target from Barclays
Incyte initiated with bullish view at Barclays, here's why